Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 518

1.

Rituximab in severe pemphigus.

Schmidt E, Goebeler M, Zillikens D.

Ann N Y Acad Sci. 2009 Sep;1173:683-91. doi: 10.1111/j.1749-6632.2009.04744.x. Review.

PMID:
19758216
2.

[Treatment of severe refractory pemphigus vulgaris with rituximab].

Pitarch G, Sánchez-Carazo JL, Pardo J, Torrijos A, Roche E, Fortea JM.

Actas Dermosifiliogr. 2006 Jan-Feb;97(1):48-51. Review. Spanish.

PMID:
16540052
3.

Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature.

Cianchini G, Corona R, Frezzolini A, Ruffelli M, Didona B, Puddu P.

Arch Dermatol. 2007 Aug;143(8):1033-8. Review.

PMID:
17709662
4.

Rituximab: a monoclonal antibody to CD20 used in the treatment of pemphigus vulgaris.

El Tal AK, Posner MR, Spigelman Z, Ahmed AR.

J Am Acad Dermatol. 2006 Sep;55(3):449-59. Review.

PMID:
16908351
5.

The efficacy and safety of rituximab in refractory pemphigus: a review of case reports.

Allen KJ, Wolverton SE.

J Drugs Dermatol. 2007 Sep;6(9):883-9. Review.

PMID:
17941359
6.

Rituximab in refractory pemphigus vulgaris.

Sorce M, Aricò M, Bongiorno MR.

Dermatol Ther. 2008 Jul;21 Suppl 1:S6-9. doi: 10.1111/j.1529-8019.2008.00194.x.

PMID:
18727815
7.

Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (rituximab).

Kong HH, Prose NS, Ware RE, Hall RP 3rd.

Pediatr Dermatol. 2005 Sep-Oct;22(5):461-4.

PMID:
16191003
8.

Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab).

Marzano AV, Fanoni D, Venegoni L, Berti E, Caputo R.

Dermatology. 2007;214(4):310-8.

PMID:
17460402
9.

Anti-B- cell-directed immunotherapy (rituximab) in the treatment of refractory pemphigus--an update.

Arin MJ, Hunzelmann N.

Eur J Dermatol. 2005 Jul-Aug;15(4):224-30. Review.

PMID:
16048747
10.

Rituximab in refractory autoimmune bullous diseases.

Schmidt E, Hunzelmann N, Zillikens D, Bröcker EB, Goebeler M.

Clin Exp Dermatol. 2006 Jul;31(4):503-8. Review.

PMID:
16716150
11.
12.

Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins.

Shimanovich I, Nitschke M, Rose C, Grabbe J, Zillikens D.

Br J Dermatol. 2008 Feb;158(2):382-8. Epub 2007 Dec 6.

PMID:
18070210
13.

Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus.

Arin MJ, Engert A, Krieg T, Hunzelmann N.

Br J Dermatol. 2005 Sep;153(3):620-5.

PMID:
16120153
14.

Two courses of rituximab (anti-CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris.

Faurschou A, Gniadecki R.

Int J Dermatol. 2008 Mar;47(3):292-4. doi: 10.1111/j.1365-4632.2008.03423.x.

PMID:
18289336
15.

Immunogenicity of rituximab in patients with severe pemphigus.

Schmidt E, Hennig K, Mengede C, Zillikens D, Kromminga A.

Clin Immunol. 2009 Sep;132(3):334-41. doi: 10.1016/j.clim.2009.05.007. Epub 2009 Jun 7.

PMID:
19502112
16.

Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin.

Ahmed AR, Spigelman Z, Cavacini LA, Posner MR.

N Engl J Med. 2006 Oct 26;355(17):1772-9.

17.

Prolonged treatment with rituximab in patients with refractory pemphigus vulgaris.

Barrera MV, Mendiola MV, Bosch RJ, Herrera E.

J Dermatolog Treat. 2007;18(5):312-4.

PMID:
17852643
18.

Rituximab in the adjuvant treatment of pemphigus vulgaris: a prospective open-label pilot study in five patients.

Goh MS, McCormack C, Dinh HV, Welsh B, Foley P, Prince HM.

Br J Dermatol. 2007 May;156(5):990-6. Epub 2007 Mar 13.

PMID:
17355229
19.

A single cycle of rituximab for the treatment of severe pemphigus.

Joly P, Mouquet H, Roujeau JC, D'Incan M, Gilbert D, Jacquot S, Gougeon ML, Bedane C, Muller R, Dreno B, Doutre MS, Delaporte E, Pauwels C, Franck N, Caux F, Picard C, Tancrede-Bohin E, Bernard P, Tron F, Hertl M, Musette P.

N Engl J Med. 2007 Aug 9;357(6):545-52.

20.

Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody).

Dupuy A, Viguier M, Bédane C, Cordoliani F, Blaise S, Aucouturier F, Bonnetblanc JM, Morel P, Dubertret L, Bachelez H.

Arch Dermatol. 2004 Jan;140(1):91-6.

PMID:
14732665

Supplemental Content

Support Center